INBRX-101
- Generic Name
- INBRX-101
- Drug Type
- Biotech
- Background
INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 130
- Registration Number
- NCT05897424
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center- Site Number : 126, Phoenix, Arizona, United States
🇺🇸David Geffen School of Medicine at UCLA- Site Number : 124, Los Angeles, California, United States
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Phase 2
Active, not recruiting
- Conditions
- Alpha 1-Antitrypsin DeficiencyEmphysema
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 99
- Registration Number
- NCT05856331
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St Joseph's Hospital and Medical Center- Site Number : 126, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath